Direkt zum Inhalt
Merck
  • Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.

Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.

The Journal of biological chemistry (2000-08-23)
R J Perrin, W S Woods, D F Clayton, J M George
ZUSAMMENFASSUNG

alpha-Synuclein has been centrally implicated in neurodegenerative disease, and a normal function in developmental synaptic plasticity has been suggested by studies in songbirds. A variety of observations suggest the protein partitions between membrane and cytosol, a behavior apparently conferred by a conserved structural similarity to the exchangeable apolipoproteins. Here we show that the capacity to bind lipids is broadly distributed across exons 3, 4, and 5 (encoding residues 1-102). Binding to phosphatidylserine-containing vesicles requires the presence of all three exons, while binding to phosphatidic acid can be mediated by any one of the three. Consistent with a "class A2" helical binding mechanism, lipid association is disrupted by introduction of charged residues along the hydrophobic face of the predicted alpha-helix and also by biotinylation of conserved lysines (which line the interfacial region). Circular dichroism spectroscopy reveals a general correlation between the amount of lipid-induced alpha-helix content and the degree of binding to PS-containing vesicles. Two point mutations associated with Parkinson's disease have little (A30P) or no (A53T) effect on lipid binding or alpha-helicity. These results are consistent with the hypothesis that alpha-synuclein's normal functions depend on an ability to undergo a large conformational change in the presence of specific phospholipids.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Avanti
16:0-18:1 PC, Avanti Polar Lipids
Avanti
16:0-18:1 PC, Avanti Polar Lipids
Avanti
16:0–18:1 PS (POPS), Avanti Polar Lipids
Avanti
16:0–18:1 PS (POPS), Avanti Polar Lipids
Avanti
16:0-18:1 PA, powder
Avanti
16:0-18:1 PA, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (sodium salt), chloroform